CHMP oks four label changes, but turns down Xgeva extension
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended label changes to four products from UCB Pharma, Baxter, Gilead Sciences and GlaxoSmithKline. Amgen, however, has not been so lucky, as the committee has turned down the company's request for an extension.